PATH's ARR growth decelerated for 12 consecutive quarters, with net-new ARR down 31% y/y in 4Q25, indicating poor revenue ...

Zacks.com users have recently been watching UiPath (PATH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Somewhere in the loop of Reuters / CNBC newswires connected to stock traders’ terminals and the @deitaone account on X that ...

Founders stepping aside for outside CEOs and then returning as CEO later on is quite a trope in the tech world, and Daniel ...

UiPath focuses on agentic automation, boasts a large ARR base, and has high gross margins. Click here to read why PATH stock is a Buy.

The ARKK fund bought 69,011 shares of CRISPR Therapeutics AG and 142,713 shares of Beam Therapeutics Inc. Based on the last ...

Cathie Wood, the founder and CEO of ARK Invest and one of the most closely watched growth investors on Wall Street, isn’t hiding from the ...

Cathie Wood, ARK Invest buy two stocks on Wednesday, Thursday as Trump tariffs rake the market. Wood previously warned of a ...

Cathie Wood’s ARK ETFs have reported their daily trades for Thursday, April 3rd, 2025, revealing a mix of significant buying and selling activity across the technology and healthcare sectors. The ...

PAYX's top line is benefiting from a solid business model, diversified products and services, and strategic acquisitions.

Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in UiPath Inc. (NYSE:PATH – Free Report) by 859.6% in the fourth quarter, according to the company in its most recent 13F filing with the ...